Biocon Chief Says No Chance For Indian Firm In M&A
This article was originally published in PharmAsia News
The head of India's Biocon biotechnology company says she does not anticipate ever selling her company. Kiran Mazumdar Shaw, chairman and managing director of the firm, said her emotional attachment to the company is too strong for her to consider selling out to another firm, as Ranbaxy Laboratories is doing. She said her loyalty and desire to expand the company probably result from her being a first-generation entrepreneur. It is often the following generations without an emotional attachment to a start-up that are willing to consider mergers and acquisitions, she said. She acknowledged, however, the state of flux in the biotechnology sector presents its own challenge to companies. (Click here for more
You may also be interested in...
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.